01487nas a2200193   4500000000100000008004100001260001200042653001200054653003000066653002000096653002900116100001300145700001600158245011800174856016700292490000600459520081400465022001401279       2020                            d  c03/202010asuramin10aAfrican sleeping sickness10aMedical history10adevelopment of treatment1 aMadeja U1 aSchroeder U00aFrom Colonial Research Spirit to Global Commitment: Bayer and African Sleeping Sickness in the Mirror of History.  uhttps://www.researchgate.net/publication/339836136_From_Colonial_Research_Spirit_to_Global_Commitment_Bayer_and_African_Sleeping_Sickness_in_the_Mirror_of_History0 v53 a<p>In the early 20th century, a series of epidemics across equatorial Africa brought African sleeping sickness (human African trypanosomiasis, HAT) to the attention of the European colonial administrations. This disease presented an exciting challenge for microbiologists across Europe to study the disease, discover the pathogen and search for an effective treatment. In 1923, the first "remedy for tropical diseases"-Suramin-manufactured by Bayer AG came onto the market under the brand name "Germanin." The development and life cycle of this product-which today is still the medicine of choice for Trypanosoma brucei (T.b), hodesiense infections-reflect medical progress as well as the successes and failures in fighting the disease in the context of historic political changes over the last 100 years.</p>  a2414-6366